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Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C,
which promotes cancer progression. The VEGF-C/VEGFR-3 axis is expressed not only by lymphatic endothelial cells but also by a
variety of human tumour cells. Activation of the VEGF-C/VEGFR-3 axis in lymphatic endothelial cells can facilitate metastasis by
increasing the formation of lymphatic vessels (lymphangiogenesis) within and around tumours. The VEGF-C/VEGFR-3 axis plays a
critical role in leukaemic cell proliferation, survival, and resistance to chemotherapy. Moreover, activation of the VEGF-C/VEGFR-3
axis in several types of solid tumours enhances cancer cell mobility and invasion capabilities, promoting cancer cell metastasis. In this
review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression.
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Tumour invasion and metastasis are the critical steps in
determining the aggressive phenotype of human cancers and the
principal cause of cancer deaths. A better understanding of the
molecular events that lead to metastasis and of the complex
interactions between metastatic cells and host factors is essential
for designing more effective cancer therapies. One of these events
is the endogenous production of growth factors that act on
tumours via functional external receptors.
The vascular endothelial growth factor (VEGF) gene family,
which encodes five polypeptide growth factors, VEGF-A, -B, -C, -D,
and -E, is particularly important because of its angiogenic and
lymphangiogenic properties that promote the growth and meta-
stasis of neoplasms (Ferrara and Davis-Smyth, 1997). Vascular
endothelial growth factors achieve this by activating related
tyrosine kinase receptors termed VEGFR-1 (Flt-1) and VEGFR-2
(KDR). These receptors are mainly expressed by endothelial cells
(Ferrara and Davis-Smyth, 1997) but are also expressed by a wide
variety of cancer cell lines (Liu et al, 1995; Strizzi et al, 2001; Wu
et al, 2003). The expression of both VEGF receptors (VEGFRs) and
their ligands, results in an autocrine function. For example, in
melanoma (Liu et al, 1995) and mesothelioma (Strizzi et al, 2001)
cells, exogenous VEGF-A stimulates cell proliferation by activating
VEGFR-2. Vascular endothelial growth factor-A also stimulates
human leukaemic cell proliferation, migration, and matrix
metalloproteinase 9 production through VEGFR-2 (Dias et al,
2002). In addition, VEGF-A induces the activation of mitogen-
activated protein kinases (MAPKs), promotes cell growth in
human pancreatic and breast cancer cells (von Marschall et al,
2000), and promotes cell adhesion and migration through
activated integrin avb3 in M21 melanoma cells (Byzova et al,
2000). These reports highlight the importance of VEGFs/VEGFRs
signaling in the biology of a variety of tumour cells and illustrate
its well-described role.
Vascular endothelial growth factor-C has been characterised as a
lymphangiogenic and angiogenic growth factor and has been
shown to signal through the receptors VEGFR-3 (also called Flt-4)
and VEGFR-2 (Plate, 2001). Vascular endothelial growth factor
receptor 3 has also been shown to be important in determining the
potential for a lymphangiogenic response. Recent studies have
indicated that VEGFR-3, which has been proposed as a marker for
lymphatic endothelial cells, is also expressed in a variety of human
malignancies. Vascular endothelial growth factor receptor 3
expression in colon cancer has been associated with poorer
survival, suggesting an axis between VEGF-C and VEGFR-3 in
colorectal cancer (Witte et al, 2002). Expression of VEGFR-3 has
also been reported to be significantly correlated with the different
stages of cervical carcinogenesis (Van Trappen et al, 2003). The
VEGF-C/VEGFR-3 axis exerts different biological effects on cancer
cells to cause tumour progression. For example, in our previous
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www.bjcancer.comstudy (Su et al, 2006), we provided evidence that the VEGF-C/
VEGFR-3 axis enhances cancer cell mobility and invasion
capabilities and promotes cancer cell metastasis.
We concluded from these various observations that, the VEGF-
C/VEGFR-3 axis, through different signaling pathways, plays a
critical role in cancer progression by regulating different cellular
functions, such as invasion, proliferation, and resistance to
chemotherapy.
THE VEGF-C/VEGFR-3 AXIS AFFECTS TUMOUR
PROGRESSION BY REGULATING
LYMPHANGIOGENESIS
Lymphangiogenesis and sustained angiogenesis are important
steps in tumour progression. Similar to angiogenesis, a tumour can
induce its own network of lymphatics that connect with the
surrounding lymphatic vessels. However, clinical and pathological
observations suggest that for many carcinomas, the transport of
tumour cells by lymphatics is the most common pathway of initial
dissemination, with cancer spread by afferent lymphatics following
routes of natural drainage. Until recently, tumour-induced
lymphangiogenesis was a relatively unfamiliar concept in the field
of cancer research.
One could envisage that overproduction of lymphangiogenic
factors may provide extra lymphatic channels, thus promoting the
spread of tumour cells. It has been reported that two members
of the VEGF family, VEGF-C and VEGF-D, not only are important
regulators of lymphangiogenesis in vivo, but also enhance
lymphatic metastasis (Karpanen and Alitalo, 2001; Skobe et al,
2001). Previous studies have demonstrated that VEGF-C is the
lymphangiogenic factor that induces the formation of lymphatic
vessels within and around tumours. In addition, these studies have
shown that VEGF-C-overexpressing tumours increase intratumoral
lymphangiogenesis by activating the VEGF-C/VEGFR-3 axis in
lymphatic endothelial cells, enhancing metastatic spread via the
lymphatics (Karpanen and Alitalo, 2001; Skobe et al, 2001). These
discoveries affect how we currently think about tumours; that is,
the spread of cancer cells from the primary tumour to the
lymphatics and blood stream, which has been previously attributed
to the general invasive properties of the tumour, is now under-
stood to be due to active recruitment of new lymphatics by
tumour-derived VEGF-C or VEGF-D (Karpanen and Alitalo, 2001;
Plate, 2001; Karkkainen et al, 2002).
In animal models, the induction of lymphangiogenesis by the
VEGF-C/VEGFR-3 axis increased tumour metastasis via the
lymphatic system (Plate, 2001; Skobe et al, 2001). Vascular
endothelial growth factor-C has been detected in many human
cancers, and a number of reports have shown a correlation
between VEGF-C expression in human tumours and the formation
of metastases in regional lymph nodes. So far, the VEGF-C levels in
several types of primary tumours have correlated significantly
with lymph node metastasis (Akagi et al, 2000; Hashimoto et al,
2001; Witte et al, 2002; Juttner et al, 2006; Su et al, 2006). However,
there are also some reports did not find a correlation between
VEGF-C expression and metastasis (Gunningham et al, 2000;
George et al, 2001; Komuro et al, 2001; Hanrahan et al, 2003;
Koyama et al, 2003).
VEGF-C overexpressing tumours not only increase intratumoral
lymphangiogenesis but also the peri-tumoral amount of lymphatic
vessels. There are several papers report that peri-tumoral, but not
intratumoral, lymphatic vessels were shown to be functional and
it was propose that lymphatic vessels at the tumour margin
may play a major role in lymphatic spread of tumour cells (Padera
et al, 2002; Gombos et al, 2005). An important point in the field
of lymphangiogenesis is to find out whether intratumour
lymphatic vessels are functional for tumour dissemination into
the lymph node.
THE ROLE OF THE VEGF-C/VEGFR-3 AXIS IN
TUMOUR CELLS
Vascular endothelial growth factor receptors are primarily
expressed by endothelial cells, but are also expressed by none-
ndothelial cell types, including several cancer cells (Weninger et al,
1999; Yonemura et al, 2001; Witte et al, 2002; Li et al, 2003;
Neuchrist et al, 2003; Van Trappen et al, 2003; Wu et al, 2003).
Vascular endothelial growth factors play a critical role in
pathological conditions by binding to and activating VEGFRs.
Many tumour cells and tumour-associated vasculature express
both VEGFRs and VEGFs, and an autocrine/paracrine function has
been proposed (Byzova et al, 2000; Dias et al, 2002).
Although expression of VEGF-C and VEGFR-3 has been
significantly and negatively correlated to the progression of certain
selective types of cancer (Table 1), the function of the VEGF-C/
VEGFR-3 axis in cancer cells is largely unknown. Vascular
endothelial growth factor receptor 3 expression in colon cancer,
which as noted earlier has been associated with poorer survival
(Witte et al, 2002) and has been significantly correlated with the
different stages of cervical carcinogenesis (Van Trappen et al,
2003), suggesting an axis between VEGF-C and VEGFR-3 in cancer
cells. However, there are some studies that did not detect VEGFR-3
expression by tumour cells (Chen et al, 2004; Zeng et al, 2004) and
these controversial results might be clarified by more powerful and
sensitive technique in the future.
Immunohistochemical staining has shown that VEGFR-3 is
expressed by Kaposi sarcoma cells (Weninger et al, 1999).
Furthermore, Marchio et al (1999) reported that tyrosine
phosphorylation of VEGFR-3 was increased in Kaposi sarcoma
cells treated with VEGF-C recombinant protein as well as C156S
mutant VEGF-C recombinant protein, a selective ligand and an
activator of VEGFR-3, although devoid of any Flt-1 activation
property. Marchio et al (1999) found that the activation of the
VEGF-C/VEGFR-3 axis in Kaposi sarcoma cells was indeed
involved in the regulation of cellular functions, such as prolifera-
tion and migration. Using endothelial cells as a control, Marchio
et al (1999) further found that the activation of the VEGF-C/
VEGFR-3 axis significantly increased the proliferation and
migration of KS IMM Kaposi sarcoma cells in a dose-dependent
manner.
The VEGF-C/VEGFR-3 axis has also been found to play a role in
the growth of malignant mesothelioma cells (Masood et al, 2003).
Indeed, both the VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 axes
are present in several malignant pleural mesothelioma cell lines,
and both axes are functionally related to cell growth. Further
supporting the role of the VEGF-C/VEGFR-3 axis in cell growth
was the finding that using VEGF-C antisense oligonucleotides,
recombinant VEGFR-3/Fc, or VEGFR-3 antibody to inhibit the
activity of the VEGF-C/VEGFR-3 axis in malignant pleural
mesothelioma cells resulted in a significant reduction in cell
viability. However, there are now many studies, including our
previous study, demonstrate that VEGF-C overexpression by
experimental tumours did not enhance tumour growth but
selectively promote tumour metastasis (Skobe et al, 2001; Hoshida
et al, 2006; Su et al, 2006). In addition, other studies have been
reported that neither expression of VEGFR-3-Ig in LNM35 lung
cancer cells (He et al, 2002) nor expression of VEGF-C-specific
small interfering RNA vector in C166 mammary tumour cells
(Chen et al, 2005) changed the tumour growth rate.
The interaction of VEGF-C with VEGFR-3 in leukaemia cells
promotes cell survival and proliferation, as shown by Dias et al
(2002) in two cell lines and in five cases of VEGFR-3
þ primary
leukaemia. In particular, these researchers observed that VEGF-C
and a mutant form of the molecule that lacks the KDR-binding
motif induced receptor phosphorylation and increased cell
proliferation and survival, as shown by increased Bcl-2/Bax ratios.
Moreover, the activation of the VEGF-C/VEGFR-3 axis protected
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agents such as cytarabine, daunorubicin, and etoposide. These
results also identified the VEGF-C/VEGFR-3 pathway as a novel
therapeutic target for the treatment of subsets of acute leukaemia.
Our recent study (Su et al, 2006) provided evidence that the
VEGF-C/VEGFR-3 axis enhances cancer cell mobility and inva-
siveness and contributes to the promotion of cancer cell metastasis
in various types of cancer, including lung adenocarcinoma, breast
cancer, cervical prostate cancer, and colorectal cancer. Further, the
VEGF-C/VEGFR-3-mediated invasion and metastasis of cancer
cells was found to require upregulation of the neural cell adhesion
molecule contactin-1 through activation of the Src-p38 MAPK-C/
EBP-dependent pathway. In agreement with the role of the
VEGF-C/VEGFR-3 axis in invasion and metastasis, an examination
of tumour tissues from various types of cancers revealed
high levels of VEGFR-3 and VEGF-C expression that correlated
closely with clinical metastasis and patient survival. The function
and molecular mechanism of the VEGF-C/VEGFR-3 axis were
revealed from in vitro and in vivo studies and in an examination
of patient outcomes.
CONCLUSIONS
The VEGF-C/VEGFR-3 axis plays a critical role in cancer
progression by inducing lymphangiogenesis and facilitating the
Table 1 Expression, function, and clinical significance of VEGFR-3 in human tumours
Tumour type Primary findings References
Gastric cancer The expression of VEGFR-3 correlated with reduced carcinoma-specific survival, and a Cox multivariate
regression analysis qualified VEGFR-3 as an independent prognostic parameter. The presence of the
VEGF-C/VEGFR-3 axis was associated with poor survival in lymph node-positive gastric cancer
Juttner et al (2006)
Breast cancer The expression of VEGFR-3 in breast cancer tissue was not significantly related to tumour grade (P¼0.063) Longatto Filho et al
(2005)
The activation of the VEGF-C/VEGFR-3 axis increased cell mobility of breast cancer cells. The expression of
VEGFR-3 in breast tumour tissue was higher than it was in matched normal tissue
Su et al (2006)
NSCLC VEGF-C and VEGFR-3 status may be indicative of survival rates for patients with T1 lung adenocarcinoma Kojima et al (2005)
VEGF-C and VEGFR-3 expression may be indicative of survival rates for patients with NSCLC Arinaga et al (2003)
In NSCLC, the VEGF-C/VEGFR-3 axis is related to lymphangiogenesis, and angiogenesis and to the occurrence
and development of lung cancers. VEGF-C expression could be a useful predictor of poor prognosis in NSCLC
Li et al (2003)
The VEGF-C/VEGFR-3 axis enhances cancer cell mobility and invasiveness and contributes to the promotion of
cancer cell metastasis Examination of tumour tissues from various types of cancers revealed high levels of
VEGFR-3 and VEGF-C expression that correlated closely with clinical metastasis and patient survival
Su et al (2006)
Leukaemia The VEGF-C/VEGFR-3 axis mediates leukaemic cell proliferation, survival, and resistance to chemotherapy The
VEGF-C/VEGFR-3 pathway is a novel therapeutic target for the treatment of subsets of acute leukaemia
Dias et al (2002)
Cervical cancer A significant positive correlation was found between VEGF-C and VEGFR-3 expression through the different
stages of cervical carcinogenesis. These findings suggest an autocrine growth stimulation pattern via VEGFR-3 in
cervical carcinoma cells
Van Trappen et al
(2003)
Colorectal
cancer
The expression of VEGFR-3 in 425% of the cancer cells was associated with significantly poorer overall survival
(Po0.05), but not with lymph node metastasis or depth of tumour invasion These results suggest that VEGFs
promote cancer growth not only by stimulating angiogenesis, but also by acting on receptors present on the
cancer cells themselves
Witte et al (2002)
The expression of VEGFR-3 in colorectal tumour tissue was higher than it was in matched normal tissue Su et al (2006)
Prostate cancer Significantly upregulated expressions of VEGF-A, VEGF-C, and VEGFR-3 were all found in malignant epithelium/
cancer cells compared with adjacent benign epithelium (Po0.01) Patients in stage D had a significantly higher
score than did patients in stage A, B, or C when comparing the expression of VEGF-C or VEGFR-3 in the
tumour area (Po0.01)
Yang et al (2006)
The increased expression of the VEGF-C /VEGFR-3 axis played a role in prostate cancer progression and in
metastasis to regional lymph nodes
Jennbacken et al (2005)
VEGFR-3 expression was associated with tumour progression and may play an important role in facilitating the
lymphatic spread of prostate carcinomas; a high level of VEGFR-3 in prostate cancer cells increases the risk of
biochemical recurrence in prostate cancer patients treated by radical prostatectomy
Li et al (2004)
Kaposi sarcoma The VEGF-C/VEGFR-3 axis stimulates the migration and proliferation of Kaposi sarcoma cells Marchio et al (1999)
Head and neck
squamous cell
carcinoma
The broad expression of the VEGF-C/VEGFR-3 axis in head and neck squamous cell carcinoma suggests
involvement in tumour lymphangiogenesis and angiogenesis, promoting tumour growth, and propagation of
cancer cells. This implies that inhibitors of lymphangiogenesis could become effective therapeutic options
Neuchrist et al (2003)
Endometrial
carcinoma
The presence of VEGF-D and VEGFR-3 in endometrial carcinoma may predict myometrial invasion and lymph
node metastasis and may prospectively identify patients who are at increased risk for poor outcome. In addition,
VEGF-D and VEGFR-3 may be promising targets for new therapeutic strategies in endometrial carcinoma
Yokoyama et al (2003)
Mesothelioma VEGF/Flt-1 and VEGF-C/VEGFR-3 autocrine loops targeting agents significantly inhibited malignant
mesothelioma cell growth
Masood et al (2003)
NSCLC¼non-small cell lung cancer; VEGF¼vascular endothelial growth factor; VEGFR¼VEGF receptor.
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C/VEGFR-3 axis may affect cancer development or progression by
directly affecting tumour cells. Unlike the well-characterised axis
of VEGF-A and VEGFR-2, there may be many undefined functions
and molecular mechanisms involved in the tumour progression
mediated by the VEGF-C/VEGFR-3 axis; thus, further study of the
axis is needed. It is also important to identify the functions of the
VEGF-C/VEGFR-3 axis in macrophage infiltration/activation and
to determine how these tumour-educated macrophages affect
tumour progression. This is because infiltrating macrophages have
correlated significantly and negatively with cancer patient prog-
nosis and survival (Ogawa et al, 2004; Schoppmann et al, 2006). It
has been reported that tumour-associated macrophages play a
crucial role in angiogenesis and lymphangiogenesis under
inflammatory condition (Cursiefen et al, 2004; Maruyama et al,
2005). It also has been reported that macrophages support
lymphangiogenesis in two different ways, either by transdiffer-
entiating and directly incorporating into the endothelial layer or by
stimulating division of pre-existent local lymphatic endothelial
cells (Kerjaschki, 2005; Maruyama et al, 2005). In our unpublished
data, we also found that VEGF-C plays a critical role in the
macrophage infiltration in lung tumour through VEGFR-3 and this
VEGFR-3-mediated macrophage infiltration may involved in
radiosensitisation of lung cancer cells.
Another important area to be further explored is the nuclear
localisation of VEGFR-3 and other VEGF receptors. This is because
many receptor tyrosine kinases are detected in the cell nucleus and
function as transcription cofactors to activate gene promoters,
such as the EGFR family (Lo and Hung, 2006). Nuclear
translocation of EGFRs has been reported to play a critical role
in cancer progression (Lo and Hung, 2006). We have found that
VEGF-C activated VEGFR-3 was translocated into the nucleus of
both lung adenocarcinoma cells and primary lymphatic endothe-
lial cells (our unpublished data). Other aspects of the physical
functions and molecular mechanisms of this nuclear localisation
remain unclear and need to be clarified.
Targeting the VEGF-C/VEGFR-3 axis may be therapeutically
significant for certain types of tumours. Thus, the continued
discovery and characterisation of factors that regulate VEGF-C or
VEGFR-3 will be essential for developing new therapies that limit
the spread of cancer. In particular, new drugs that block the VEGF-
C/VEGFR-3 signaling pathway may provide useful anticancer
therapeutics by mechanisms other than the blockage of lymphan-
giogenesis. In addition to being potential targets for inhibiting
tumour metastasis, factors implicated in tumour lymphangiogen-
esis and the specific molecules found on the activated lymphatic
endothelium may prove valuable in the diagnosis of particularly
aggressive metastatic cancers.
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